SANYRES XXI, Córdoba, Spain.
Exp Mol Med. 2010 Feb 28;42(2):87-98. doi: 10.3858/emm.2010.42.2.010.
Parathyroid hormone-related protein (PTHrP) is synthesized by diverse tissues, and its processing produces several fragments, each with apparently distinct autocrine and paracrine bioactivities. In bone, PTHrP appears to modulate bone formation in part through promoting osteoblast differentiation. The putative effect of PTH-like and PTH-unrelated fragments of PTHrP on human mesenchymal stem cell (MSCs) is not well known. Human MSCs were treated with PTHrP (1-36) or PTHrP (107-139) or both (each at 10 nM) in osteogenic or adipogenic medium, from the start or after 6 days of exposure to the corresponding medium, and the expression of several osteoblastogenic and adipogenic markers was analyzed. PTHrP (1-36) inhibited adipogenesis in MSCs and favoured the expression of osteogenic early markers. The opposite was observed with treatment of MSCs with PTHrP (107-139). Moreover, inhibition of the adipogenic differentiation by PTHrP (1-36) prevailed in the presence of PTHrP (107-139). The PTH/PTHrP type 1 receptor (PTH1R) gene expression was maximum in the earlier and later stages of osteogenesis and adipogenesis, respectively. While PTHrP (107-139) did not modify the PTH1R overexpression during adipogenesis, PTHrP (1-36) did inhibit it; an effect which was partially affected by PTHrP (7-34), a PTH1R antagonist, at 1 microM. These findings demonstrate that both PTHrP domains can exert varying effects on human MSCs differentiation. PTHrP (107-139) showed a tendency to favor adipogenesis, while PTHrP (1-36) induced a mild osteogenic effect in these cells, and inhibited their adipocytic commitment. This further supports the potential anabolic action of the latter peptide in humans.
甲状旁腺激素相关蛋白 (PTHrP) 由多种组织合成,其加工产生几种片段,每个片段都具有明显不同的自分泌和旁分泌生物活性。在骨骼中,PTHrP 似乎通过促进成骨细胞分化来调节骨形成。PTHrP 的 PTH 样和与 PTH 无关的片段对人骨髓间充质干细胞 (MSCs) 的潜在影响尚不清楚。将人 MSCs 用 PTHrP(1-36) 或 PTHrP(107-139) 或两者(均为 10 nM)在成骨或成脂培养基中处理,从开始或在暴露于相应培养基 6 天后开始,并分析几种成骨细胞和成脂细胞标志物的表达。PTHrP(1-36) 抑制 MSCs 的脂肪生成,并有利于成骨早期标志物的表达。用 PTHrP(107-139) 处理 MSCs 则观察到相反的结果。此外,PTHrP(1-36) 抑制脂肪生成的作用在存在 PTHrP(107-139) 时占主导地位。PTH/PTHrP 型 1 受体 (PTH1R) 基因表达在成骨和脂肪生成的早期和晚期阶段分别达到最大值。虽然 PTHrP(107-139) 不会改变脂肪生成过程中的 PTH1R 过表达,但 PTHrP(1-36) 会抑制这种过表达;该作用部分受 1 μM 的 PTH1R 拮抗剂 PTHrP(7-34) 影响。这些发现表明,PTHrP 的两个结构域都可以对人 MSCs 分化产生不同的影响。PTHrP(107-139) 显示出促进脂肪生成的趋势,而 PTHrP(1-36) 在这些细胞中诱导轻度成骨作用,并抑制其脂肪细胞分化。这进一步支持了后者肽在人体内的潜在合成代谢作用。